Corporation: Investors and Media: Cyanotech Corporation Guerrant Associates Gerald R. Cysewski Ph.D. Laura Guerrant (808) 326-1353 (808) 882-1467 info@cyanotech.com lguerrant@guerrantir.co

CYANOTECH CORPORATION ANNOUNCES

RESULTS OF INDEPENDENT LABORATORY TESTING OF

KAILUA KONA, Hawaii. - June 8, 2005 - Cyanotech

Corporation (Nasdaq SmallCap: CYAN) a world leader in producing high-value

natural products from microalgae, today announced the results of testing done at

the Department of Biological Sciences at Wright State University (Dayton, Ohio),

on Spirulina Pacifica confirming the absence of BMAA.

An article, Diverse taxa of cyanobacteria produce

b-N-methylamino-L-Alanine, a neurotoxic amino acid by Cox et al., appeared in

the April 2005 issue of the Proceedings of the

National Academy of Sciences (PNAS 102:5074-5078). This study showed a potential toxin, BMAA,

was found in diverse groups of cyanobacteria, which may have raised some

concern over the safety of Spirulina, a product sold worldwide as a dietary

supplement. On April 13, 2005,

Cyanotech Corporation filed a Form 8-K with the Securities &

Exchange Commission in response to a press release issued by Earthrise Nutritionals,

LLC which cited such concern and mentioned Cyanotech.

Spirulina (Arthrospira) was not included among the

30 types of cyanobacteria tested and referenced in the article. Cyanotech,

however, took the precautionary measure of submitting samples of its spirulina

products for independent testing for BMAA.

The Company first approached Dr. Paul Alan Cox, the primary

researcher and co-author of the PNAS article, who did not respond to the request. The Company then enlisted the services of

Professor Wayne W. Carmichael to test its Spirulina product. Professor Carmichael is a full Professor in

the Department of Biological Sciences at Wright State University and a leading

expert in the field of cyanobacterial toxins.

On June 3, 2005, Professor Carmichael reported his findings confirming

the absence of detection levels of the suspected neurotoxin BMAA in Cyanotech s

The results of the test confirm that our Spirulina

contains no trace of BMAA and we are pleased to provide this reassurance to our

customers of the integrity of our products, said Gerald R. Cysewski, Ph.D.,

Chairman, President and Chief Executive Officer. One of the primary goals of Cyanotech is to

offer microalgal products which provide high value to our customers and this

affirmation of the absence of detectable BMAA in our Spirulina is further

evidence of our commitment to quality and safety of our products.

Cyanotech Corporation, a world leader in microalgal

technology, produces high-value natural products from microalgae and is the

world s largest commercial producer of natural astaxanthin (pronounced asta-zan-thin )

from microalgae. Products include

BioAstin natural astaxanthin, a powerful antioxidant with expanding

applications as a human nutraceutical; NatuRose natural astaxanthin for the

aquaculture and animal feed industries; Spirulina Pacifica , a nutrient-rich

dietary supplement; and phycobiliproteins, which are fluorescent pigments used

in the immunological diagnostics market.

Spirulina Pacifica and BioAstin are sold directly online through the

Company s website, www.nutrex-hawaii.com, as well as through resellers in over

30 countries worldwide. Technical

information for the Company s phycobiliproteins products is available at

www.phycobiliprotein.com. Corporate data and other product information are

available at www.cyanotech.com.

Safe Harbor Statement under the Private

Securities Litigation Reform Act of 1995

Except for statements of

historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of

risks and uncertainties that could cause actual results to differ materially

from the statements made. These factors

include, but are not limited to, general economic conditions, forecasts of

sales in future periods, changes in sales levels to our largest customers,

weather patterns, production problems caused by contamination, risks associated

with the acceptance of new products, competition, foreign exchange

fluctuations, government regulation, and other factors more fully detailed in

the Company s recent Form 10-Q and annual form 10-K filings with the

Securities and Exchange Commission.